BostonPremier Wealth LLC Has $573,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

BostonPremier Wealth LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 24.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,453 shares of the company’s stock after selling 1,107 shares during the quarter. Johnson & Johnson comprises 0.4% of BostonPremier Wealth LLC’s holdings, making the stock its 24th largest holding. BostonPremier Wealth LLC’s holdings in Johnson & Johnson were worth $573,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in JNJ. Tallon Kerry Patrick bought a new position in shares of Johnson & Johnson in the 4th quarter worth about $290,000. Capital & Planning LLC grew its stake in Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after purchasing an additional 183 shares during the period. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $85,886,000. Finally, Strategic Financial Concepts LLC boosted its holdings in shares of Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after buying an additional 1,271 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Wall Street Zen downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Raymond James Financial cut their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday, April 14th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Finally, Bank of America dropped their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Trading Down 1.1%

NYSE JNJ opened at $150.77 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The business has a fifty day simple moving average of $154.11 and a 200 day simple moving average of $153.64. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a market capitalization of $362.76 billion, a P/E ratio of 16.77, a PEG ratio of 2.28 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.45%. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.